3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Conditions
Ovarian Neoplasms
14
Fallopian Tube Neoplasms
12
Breast Neoplasms
8
Prostatic Neoplasms
7
Neoplasms
7
Carcinoma, Ovarian Epithelial
6
Endometrial Neoplasms
5
Pancreatic Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Metastatic Castration Resistant Prostate Cancer
2
Lung Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Transitional Cell
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Myeloproliferative Disorders
1
Interventions
padeliporfin
5
Pluvicto
2
Paclitaxel
2
Abiraterone Acetate
2
sipuleucel-T
1
rucaparib
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
onapristone
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
ixabepilone
1
gallium 68 PSMA-11
1
apalutamide
1
abiraterone
1
Therapeutics
1
Suspensions
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Powders
1
Nivolumab
1
Leuprolide
1
Ipilimumab
1
Imatinib Mesylate
1
Gemcitabine
1
EPI-506
1
Cisplatin
1
Chemical Fractionation
1
Biopsy, Needle
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Genital Neoplasms, Male
×
rucaparib
×
Clear all
NCT04676334
2024-05-07
CATCH-R
pharmaand GmbH
Phase 3
Completed
34 enrolled
9 charts